Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2026)
Recursion Pharmaceuticals (RXRX) reported Income from Continuing Operations of 117504000.0 for Q1 2026, up 41.97% on a YoY basis from 82767010.29 in Q1 2025, and down 8.68% quarter-over-quarter from 108122000.0 in Q4 2025.
Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals has reported Income from Continuing Operations for 7 years, with the latest figure at 117504000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 41.97% year-over-year to 117504000.0; the trailing twelve-month figure through Mar 2026 stood at 559776000.0 (up 2.61% YoY), and the FY2025 full-year result was 644759000.0, down 39.06% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 117504000.0, down from 108122000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 55981000.0 in Q1 2022, with the low at 202487000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 105865705.88 across 5 years, with a median of 93017000.0 in 2023.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations slumped 121.6% — and 2026, when it soared 41.97%.
- Recursion Pharmaceuticals' Income from Continuing Operations stood at 60982000.0 in 2022, then plunged by 52.5% to 92996000.0 in 2023, then tumbled by 92.38% to 178906000.0 in 2024, then jumped by 39.56% to 108122000.0 in 2025, then slipped by 8.68% to 117504000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 117504000.0 (Q1 2026), 108122000.0 (Q4 2025), and 162253000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | -117.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.50 Mn |
| Dec 31, 2025 | -108.12 Mn |
| Sep 30, 2025 | -162.25 Mn |
| Jun 30, 2025 | -171.90 Mn |
| Mar 31, 2025 | -202.49 Mn |
| Dec 31, 2024 | -178.91 Mn |
| Sep 30, 2024 | -95.84 Mn |
| Jun 30, 2024 | -97.54 Mn |
| Mar 31, 2024 | -91.37 Mn |
| Dec 31, 2023 | -93.00 Mn |
| Sep 30, 2023 | -93.02 Mn |
| Jun 30, 2023 | -76.73 Mn |
| Mar 31, 2023 | -65.33 Mn |
| Dec 31, 2022 | -60.98 Mn |
| Sep 30, 2022 | -62.57 Mn |
| Jun 30, 2022 | -66.19 Mn |
| Mar 31, 2022 | -55.98 Mn |
| Dec 31, 2021 | -64.96 Mn |
| Sep 30, 2021 | -46.40 Mn |
| Jun 30, 2021 | -40.93 Mn |